Today, shares of GBS (NASDAQ:GBS) are skyrocketing following news that “the company will start preparation for clinical trials of its rapid SARS-CoV-2 antibody test.” GBS’s antibody test utilizes ...
Redesigned test introduces two new targets to improve coverage and sensitivity for Group B Streptococcus intrapartum testing for pregnant females Group B Streptococcus (GBS) is the leading cause of ...
SUNNYVALE, Calif., Nov. 16, 2022 /PRNewswire/ -- Cepheid today announced the availability of Xpert ® GBS LB XC (extended coverage), a molecular diagnostic test for qualitative detection of Group B ...
Redesigned test introduces two new targets to improve coverage and sensitivity for Group B Streptococcus intrapartum testing for pregnant females With the capability of returning positive results as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results